Career Development Office - MIT Sloan School of Management

Q.  Earlier this year, McKinsey shared research findings of how while organizations have seen usage with gen AI tools surge, from a value capture standpoint, “…these are still early days—few are experiencing meaningful bottom-line impacts.”[1]  And this analysis builds …

 Fall 2025 (Class of 2026) – Winter/Spring 2026 (Class of 2027)

The CDO has gathered offer deadline info from McKinsey, Bain & BCG for the Fall 2025 and Winter/Spring 2026 recruiting season.  These offer deadlines are earlier than our specified policy …

Much of the conversation about healthcare innovation is dominated by breakthroughs in new pharmaceutical therapies. While many drug treatments are truly lifesaving, Karthik Kuppusamy, PhD, Senior Vice President of Clinical Solutions at Quest Diagnostics, argues that detecting disease in its …

I am planning for full-time recruiting. What should I do now?

Reflect on your experience, career direction, and network: 
An internship is an excellent opportunity to solidify your career decision, identify your area of focus, or even consider a different …

The integration of AI in pharmaceutical research and development (R&D) holds immense potential to accelerate drug discovery, optimize clinical operations, and improve patient outcomes. However, a persistent challenge remains: the data gap. AI-driven models are only as strong as the …

By Eliza Weaver, MBA ’26

When I arrived at MIT Sloan last August, “start a running-tech company” wasn’t on my roadmap. I’d spent my career building B2B software at Workday—first as a software engineer, then as a product manager—after earning …

There are two schools of thought: one sees AI as a force multiplier for societal good, and the other envisions a doomsday scenario. Do you foresee any existential or catastrophic AI risk? If so, how so?

Let me begin with …

Brian Eastwood | MIT Sloan – Ideas Made to Matter | June 10, 2025

What impact will AI and emerging technologies have on the U.S. labor force? Since the arrival of ChatGPT a little less than three years ago, such debates have …

By Mikael Petrosyan, MIT Sloan Fellow MBA ’22 and Vice President, SDP Boston Chapter

As an MIT alum, it’s always a privilege to return to campus — but it’s even more meaningful when it’s to co-host an event that brings together …

Balyasny Asset Management’s head of quantitative research talks algos, hedge funds, correlations and cats

Robin Wigglesworth I Financial Times I June 12, 2025

Morning! After some dabbling in the genre, FT Alphaville is starting an informal series of simple Q&A …